Press Release

MONTREAL, November 2nd, 2020 – Replicor Inc., a privately held biopharmaceutical company targeting functional cure for patients with chronic hepatitis B and D infection, announced the acceptance of four presentations at the 2020 digital meeting of the American Association for the Study of the Liver (AASLD / TLMdX) being held from November 13-16, 2020.
These presentations include the following advances:
Identification of the host HSP40 chaperone DNAJB12 as the target for NAPs in the selective inhibition of subviral particle (SVP) assembly and secretion (Poster LP42).
Well tolerated compassionate use of TDF and REP 2165-Mg in a cirrhotic individual with HBV / HDV coinfection, achieving simultaneous clearance of HDV RNA and HBsAg and HBsAg seroconversion (Poster 0827).
In collaboration with Abbott Diagnostics, analysis of HBsAg isoforms in the REP 301 and REP 401 studies providing evidence for the selective targeting of SVP by REP 2139 in humans (Poster 0819).
Demonstration of the inhibition of HBsAg secretion by REP 2139 in a novel cell line expressing only HBsAg and HBx (Poster 0818).
Replicor’s CSO, Dr. Andrew Vaillant commented, “The identification of DNAJB12 as the host NAP target in HBV infection is an important step in understanding the selectivity of the NAP effect for SVP. With the confirmation of the NAP effect in humans via HBsAg isoform analysis and the safe and effective use of NAPs in a cirrhotic patient, these presentations provide important advances in the understanding of the clinical effects of NAPs and expanding their use in all patients with HBV infection.”
Replicor’s presentations from TLMdX will become available on the company’s website following the meeting at www.replicor.com/science/conference-presentations. For further information about the 2020 AASLD meeting (TLMdX), please see https://tlmdx.aasld.org/.

About Replicor
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further information about Replicor please visit our website at www.replicor.com.